Stephen S. Whitehead focuses on Virology, Dengue virus, Virus, Dengue fever and Dengue vaccine. He studies Virology, namely Neutralizing antibody. The study incorporates disciplines such as Serotype, Microbiology, Flavivirus and Vaccination in addition to Dengue virus.
His Virus research is multidisciplinary, incorporating elements of Molecular biology, Recombinant virus and Gene. His primary area of study in Dengue fever is in the field of Antibody-dependent enhancement. As a part of the same scientific study, he usually deals with the Dengue vaccine, concentrating on Viremia and frequently concerns with Clinical endpoint and Rash.
Stephen S. Whitehead mostly deals with Virology, Dengue virus, Virus, Dengue fever and Immunology. As a part of the same scientific study, Stephen S. Whitehead usually deals with the Virology, concentrating on Antibody and frequently concerns with Zika virus. His Dengue virus research is multidisciplinary, incorporating perspectives in Viremia, Serotype, Immunity, Attenuated vaccine and Epitope.
Stephen S. Whitehead interconnects Molecular biology and Recombinant DNA in the investigation of issues within Virus. Stephen S. Whitehead works mostly in the field of Dengue fever, limiting it down to concerns involving T cell and, occasionally, Antigen. Stephen S. Whitehead has included themes like Titer and Immunogenicity in his Neutralizing antibody study.
Stephen S. Whitehead spends much of his time researching Virology, Dengue virus, Dengue fever, Flavivirus and Dengue vaccine. His work deals with themes such as Attenuated vaccine and Antibody, which intersect with Virology. Dengue virus is a subfield of Immunology that he explores.
His work carried out in the field of Dengue fever brings together such families of science as Immune system and B cell. His Dengue vaccine research includes themes of Internal medicine, Clinical trial, Disease and Seroconversion. The various areas that Stephen S. Whitehead examines in his Virus study include Exome sequencing and Chronic infection.
Stephen S. Whitehead mainly investigates Virology, Dengue virus, Virus, Zika virus and Immunity. Virology is closely attributed to Disease in his work. Specifically, his work in Dengue virus is concerned with the study of Dengue vaccine.
His Virus research integrates issues from Fetus and Antibody. His studies in Immunity integrate themes in fields like Platelet, Genetic variation, Genotype and Dengue fever. His study in Vaccination is interdisciplinary in nature, drawing from both Epitope, Attenuated vaccine, Serotype and Flavivirus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prospects for a dengue virus vaccine.
Stephen S. Whitehead;Joseph E. Blaney;Anna P. Durbin;Brian R. Murphy.
Nature Reviews Microbiology (2007)
The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity
Martina Beltramello;Katherine L. Williams;Cameron P. Simmons;Annalisa Macagno.
Cell Host & Microbe (2010)
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.
Ruth A. Karron;Deborah A. Buonagurio;Alice F. Georgiu;Stephen S. Whitehead.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Immune Response to Dengue Virus and Prospects for a Vaccine
Brian R Murphy;Stephen S Whitehead.
Annual Review of Immunology (2011)
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
Anna P. Durbin;Ruth A. Karron;Wellington Sun;David W. Vaughn.
American Journal of Tropical Medicine and Hygiene (2001)
Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse.
Alexander Bukreyev;Stephen S. Whitehead;Brian R. Murphy;Peter L. Collins.
Journal of Virology (1997)
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
Peter F. Wright;Ruth A. Karron;Robert B. Belshe;Juliette Thompson.
The Journal of Infectious Diseases (2000)
Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees
Stephen S. Whitehead;Alexander Bukreyev;Michael N. Teng;Cai Yen Firestone.
Journal of Virology (1999)
Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.
Michael N. Teng;Stephen S. Whitehead;Peter L. Collins.
Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees.
Michael N. Teng;Stephen S. Whitehead;Alison Bermingham;Marisa St. Claire.
Journal of Virology (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: